局部晚期宫颈癌中等大分割在线自适应放疗的III期随机对照试验方案
SWIFT-1是一项多中心、开放标签、双臂、III期随机对照非劣效性试验,计划纳入440例局部晚期宫颈癌患者,1:1随机接受中等大分割在线自适应放疗(MHRT组:43.35 Gy/17次,阳性淋巴结同步推量54.4 Gy/17次)或常规分割放疗(CFRT组:45 Gy/25次,阳性淋巴结同步推量60 Gy/25次),两组均接受同步放化疗,部分 eligible 患者接受免疫治疗。主要终点为3年无进展生存期,旨在评估MHRT对比CFRT的非劣效性。
要点
- MHRT组处方剂量43.35 Gy/17次,阳性淋巴结同步推量54.4 Gy/17次。
- CFRT组处方剂量45 Gy/25次,阳性淋巴结同步推量60 Gy/25次。
- 主要终点为3年无进展生存期,计划样本量440例。
核心结论
- 该试验将前瞻性评估中等大分割在线自适应放疗对比常规分割放疗在局部晚期宫颈癌中的疗效与安全性非劣效性。
研究设计与样本
- 多中心、开放标签、双臂、III期随机对照非劣效性试验,计划纳入440例局部晚期宫颈癌患者,按1:1随机分组。
- 两组均接受同步放化疗,部分符合条件的患者接受免疫治疗。
主要发现
- 原文未报告研究结果,仅描述试验设计与终点。
关键数值与推荐
- MHRT组体外放疗处方剂量43.35 Gy/17次,阳性淋巴结同步推量54.4 Gy/17次。
- CFRT组体外放疗处方剂量45 Gy/25次,阳性淋巴结同步推量60 Gy/25次。
- 主要终点为3年无进展生存期。
- 次要终点包括完全缓解率、体外放疗后肿瘤退缩、总生存期、局部区域无进展生存期、无转移生存期、宫颈癌特异性生存期、急性和晚期毒性及生活质量。
临床怎么用
- 该试验旨在为局部晚期宫颈癌使用中等大分割在线自适应放疗替代常规分割放疗提供高质量证据。
局限性
- 原文为研究方案,尚未报告实际研究结果。
- 原文指出既往许多研究缺乏现代放疗技术整合,可能高估中等大分割放疗相关毒性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: External beam radiotherapy (EBRT) is an essential component of standard treatment for locally advanced cervical cancer. Moderately hypofractionated radiotherapy (MHRT) offers the potential to reduce treatment burden while compromising efficacy. Although various studies have investigated the safety and efficacy of MHRT, high-quality evidence remains inadequate. The lack of integration of modern radiotherapy techniques in many existing studies may lead to an overestimation of MHRT-associated toxicity. METHODS: This prospective, multi-center, randomized controlled, non-inferiority phase III trial aims to evaluate the non-inferiority of moderately hypofractionated online adaptive radiotherapy (oART) compared to conventional fractionated radiotherapy (CFRT). A total of 440 participants will be enrolled and randomly assigned in a 1:1 ratio to either the MHRT or CFRT group. Both groups will receive concurrent chemoradiotherapy, and a subset of eligible patients will undergo immunotherapy. The prescribed EBRT dose for the MHRT group will be 43.35 Gy in 17 fractions, with a simultaneous integrated boost of 54.4 Gy in 17 fractions to positive lymph nodes. The CFRT group will receive 45 Gy in 25 fractions, with a simultaneous integrated boost of 60 Gy in 25 fractions to positive lymph nodes. The primary endpoint will be 3-year progression-free survival. Secondary endpoints will include the complete response rate, tumor regression following EBRT, overall survival, locoregional progression-free survival, metastasis-free survival, cervical cancer-specific survival, acute and late toxicity, and quality of life. DISCUSSION: This randomized controlled trial will prospectively investigate whether MHRT is non-inferior to conventional fractionation in terms of efficacy and safety. Furthermore, the trial will evaluate the potential of moderately hypofractionated oART as a clinically viable alternative to CFRT for the treatment of locally advanced cervical cancer. TRIAL REGISTRATION: This trial was registered at ClincalTrials.gov (NCT06641635) on October 12, 2024.
引用
- Zeng Z, Chen Y, Qiu J, et al. Moderately hypofractionated online adaptive radiotherapy (SWIFT-1) in cervical cancer patients: study protocol for a multi-centered, open-label, two-arm, phase III, randomized controlled study. Radiat Oncol. 2025. PMID: 40671096. doi:10.1186/s13014-025-02688-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。